Potent carbonic anhydrase I, II, IX and XII inhibition activity of novel primary benzenesulfonamides incorporating bis-ureido moieties

Figures & data

Figure 1. The design strategy of novel bis-ureido substituted primary benzenesulfonamides 8–19.

Scheme 1. General synthetic route for the synthesis of the primary benzenesulfonamides incorporating bis-ureido moieties 8–19.

Table 1. Inhibition data of human CA isoforms hCA I, hCA II, hCA IX and hCA XII with bis-ureido-substituted primary benzenesulfonamide derivatives (8–19) reported here and standard sulphonamide inhibitor Acetazolamide (AAZ) by a stopped flow CO₂ hydrase assay.

			KI^a (nM)
Cmp	X	Y	hCA I	hCA II	hCA IX	hCA XII
8			7279	680	57.5	37.3
9			6282	484	835	429
10			947	302	86.4	52.3
11			68.1	4.4	6.73	7.39
12			6519	550	63.8	63.2
13			9174	306	78.7	27.7
14			688	637	578	67.9
15			5002	80.8	81.1	67.1
16			2915	424	68.7	82.8
17			5351	792	91.9	33.6
18			8313	604	93.7	60.3
19			95.4	25.8	8.92	5.0
AAZ	–	–	250	12	2.5	25

^aErrors in the range of $\pm$ standart error, from 3 different assays, by a stopped flow technique.